Version: Draft v0.1 | ⚠️ All dosages require confirmation by the clinical team
A.1 Immunosuppressive Agents
| Tacrolimus |
0.03 mg/kg/h IV → oral BID |
IV → PO |
Trough level (see below) |
Nephrotoxicity, diabetes, neurotoxicity |
| Cyclosporine |
5 mg/kg/day in 2 doses |
PO BID |
Trough level |
Nephrotoxicity, gingival hyperplasia |
| MMF |
<50kg: 500mg/day; ≥50kg: 1000mg/day |
PO BID |
CBC |
GI toxicity, myelosuppression |
| Azathioprine |
1-2 mg/kg/day |
PO QD |
CBC |
Myelosuppression, hepatotoxicity |
| Prednisolone |
Maintenance 5 mg/day |
PO QD |
Blood glucose, bone density |
Osteoporosis, diabetes, infection |
| Methylprednisolone |
500-1000 mg (intraoperative); 500 mg x 3 (pulse) |
IV |
— |
— |
| Basiliximab |
20 mg Day 0 & Day 4 |
IV |
— |
Hypersensitivity (rare) |
| ATG (Thymoglobulin) |
1.5 mg/kg/day x 3-5 days |
IV |
CBC (lymphocytes) |
Severe leukopenia, infection |
| Rituximab |
375 mg/m² |
IV |
CD20 |
Infection, infusion reaction |
| Sirolimus |
1-2 mg/day (target 5-8 ng/mL) |
PO QD |
Trough level |
⚠️ Contraindicated within 3 months post-op |
| Everolimus |
0.75 mg BID (target 3-8 ng/mL) |
PO BID |
Trough level |
Oral ulcers, hyperlipidemia |
Tacrolimus Target Levels
| 0-3 months |
9-12 |
| 3-6 months |
8-11 |
| > 6 months |
7-10 |
| During infection |
5-7 |
A.2 Anti-Infective Agents
Antibiotics
| Piperacillin-Tazobactam |
4.5 g IV q6h |
Perioperative empiric |
|
| Meropenem |
1 g IV q8h |
Alternative empiric |
|
| Vancomycin |
15-20 mg/kg IV q8-12h |
MRSA coverage |
Trough 15-20 |
| TMP-SMX |
SS 1 tab QD or DS 3x/week |
PCP prophylaxis |
Lifelong |
| Azithromycin |
250 mg PO QOD |
CLAD (BOS) |
Long-term |
Antivirals
| Valganciclovir |
900 mg PO QD (prophylaxis); 900 mg BID (treatment) |
CMV |
Adjust for eGFR |
| Ganciclovir |
5 mg/kg IV q12h |
CMV tissue disease |
|
| Acyclovir |
400 mg PO BID (prophylaxis); 10 mg/kg IV q8h (treatment) |
HSV/VZV |
|
| Oseltamivir |
75 mg PO BID x 5 days |
Influenza |
|
Valganciclovir Renal Dose Adjustment
| ≥ 60 |
900 mg QD |
900 mg BID |
| 40-59 |
450 mg QD |
450 mg BID |
| 25-39 |
450 mg QOD |
450 mg QD |
| 10-24 |
450 mg 2x/week |
450 mg QOD |
Antifungals
| Amphotericin B nebulized |
Institutional protocol |
Inhaled prophylaxis |
3-6 months post-op |
| Voriconazole |
6 mg/kg IV q12h D1 → 4 mg/kg q12h |
Invasive Aspergillosis |
⚠️ Tac interaction |
| Itraconazole |
200 mg PO BID |
Prophylaxis/treatment |
⚠️ Tac interaction |
| Caspofungin |
70 mg D1 → 50 mg/day |
Alternative/salvage |
|
| Amphotericin B liposomal |
3-5 mg/kg/day IV |
Salvage |
Nephrotoxicity |
A.3 Analgesia and Sedation
| Propofol |
0.5-3 mg/kg/h IV |
ICU sedation |
First-line |
| Dexmedetomidine |
0.2-0.7 μg/kg/h IV |
Adjunctive sedation |
Facilitates weaning |
| Remifentanil |
0.05-0.2 μg/kg/min IV |
ICU analgesia |
Ultra-short acting |
| Fentanyl |
25-100 μg/h IV |
Alternative opioid |
|
| Acetaminophen |
1 g IV/PO q6h (max 4g/day) |
Non-opioid |
Monitor hepatic function |
| Gabapentin |
100-300 mg TID |
Neuropathic pain |
Renal dose adjustment |
| Ketamine |
0.1-0.3 mg/kg/h IV |
Opioid-sparing |
Low dose |
A.4 VTE Prophylaxis
| Enoxaparin |
4000 IU SC QD |
6-8h post-op |
Standard |
| Enoxaparin (on ECMO) |
0.5 mg/kg SC BID |
During ECMO |
Vienna protocol |
| UFH (on ECMO) |
continuous IV (per aPTT) |
During ECMO |
Alternative |
A.5 Other Commonly Used Medications
| Norepinephrine |
0.01-0.5 μg/kg/min IV |
Vasopressor |
First-line vasopressor |
| Dobutamine |
2-10 μg/kg/min IV |
Inotrope |
|
| Milrinone |
0.25-0.75 μg/kg/min IV |
Inotrope + pulmonary vasodilator |
|
| iNO |
10-20 ppm |
Pulmonary hypertension |
|
| Furosemide |
20-80 mg IV/PO |
Diuresis |
Target negative balance |
| Amlodipine |
5-10 mg PO QD |
Hypertension |
First-line antihypertensive |
| Pravastatin |
20-40 mg PO QHS |
Hyperlipidemia |
Minimal CYP3A interaction |
| Pantoprazole |
40 mg PO/IV QD |
Acid suppression |
|
| Calcium |
1200 mg/day PO |
Osteoporosis prevention |
|
| Vitamin D |
800-1000 IU/day PO |
Osteoporosis prevention |
Target 25-OH-D > 30 |
A.6 Drug Interaction Alert Table
| Voriconazole |
⬆⬆⬆ |
Pre-emptively reduce Tac to 1/3-1/5, check level at 48-72h |
| Itraconazole |
⬆⬆⬆ |
Same as above |
| Fluconazole |
⬆⬆ |
May require dose reduction |
| Erythromycin |
⬆⬆ |
Avoid or monitor closely |
| Diltiazem |
⬆⬆ |
Avoid for antihypertensive use |
| Nirmatrelvir-Ritonavir |
⬆⬆⬆⬆ |
Hold Tac, monitor closely |
| Rifampin |
⬇⬇⬇ |
Contraindicated → switch to Rifabutin |
| Phenytoin |
⬇⬇ |
Significant Tac dose increase required |
| Simvastatin |
Rhabdomyolysis risk |
Switch to Pravastatin |
| Grapefruit |
⬆ |
Patient education to avoid |
⚠️ This table is for quick reference only. For complete drug interaction information, consult the pharmacopoeia or a pharmacist.